Recently, it has been reported that combined inhibition of EGFR-TKIs (erlotinib) and TGF-β type I receptor inhibitor may improve sensitivity of EGFR-TKIs in lung cancer without EGFR T790M mutation [60]. The gene discussed is EGFR; the disease is lung carcinoma.